Commercial LaunchHeartBeam is well prepared for a pilot commercial launch and a full launch in 2026.
FDA ClearanceHeartBeam's proprietary system for arrhythmia assessment has received FDA clearance for a cable-free, patient-held device with 12-lead ECG accuracy.
Strategic PartnershipsInbound interest from potential strategic partners has accelerated with discussions around data and AI, complementary diagnostics and treatments, and distribution.